Functional analysis of the impact of ORMDL3 expression on inflammation and activation of the unfolded protein response in human airway epithelial cells
© Hsu and Turvey; licensee BioMed Central Ltd. 2013
Received: 3 December 2012
Accepted: 7 January 2013
Published: 1 February 2013
The gene ORMDL3 was shown to be associated with early-onset asthma susceptibility in multiple independent genome-wide and candidate-gene association studies. Asthmatic patients have elevated expression levels of this gene. ORMDL3 encodes a transmembrane protein localized in the endoplasmic reticulum (ER) that may be involved in ER stress and inflammation. It is essential to validate the genetic associations linking ORMDL3 with asthma through functional studies that confirm the biological relevance of this gene in disease. We investigated the effects of manipulating ORMDL3 expression levels in vitro in airway cells on innate immune inflammatory responses, ER stress and activation of the unfolded protein response (UPR).
ORMDL3 expression levels were manipulated in airway cells using an overexpression plasmid and siRNA technologies. Successful modulation of ORMDL3 was confirmed at both the gene and protein level. The functional impact of modulation of ORMDL3 expression levels on inflammatory responses and activation of the UPR were quantified using complementary cellular and molecular immunology techniques.
Cells with altered ORMDL3 levels responded equally well to innate immune stimuli and produced similar levels of pro-inflammatory cytokines compared to wild-type cells. Treatment with ER stress inducers, thapsigargin and tunicamycin, resulted in activation of the unfolded protein response (UPR). However, we observed no difference in UPR activation in cells with ORMDL3 knockdown compared to cells with normal ORMDL3 levels.
Our results suggest that ORMDL3 variation in the airway epithelium is unlikely to play a significant role in modulating innate immune responses and the UPR in the lung.
KeywordsImmune response Epithelium Cytokines Chemokines Host defense
Asthma and allergic diseases are rapidly becoming the most common chronic diseases in the developed world. Current asthma therapy treats symptoms of the disease, however it is ineffective in up to 25% of patients . Asthma and allergic diseases are complex disorders caused by the interaction of various genetic and environmental factors [2–4].
Genome-wide association studies (GWAS) have been used to identify genes that may be involved in asthma pathogenesis . Moffatt and colleagues first reported that multiple single nucleotide polymorphisms (SNPs) on chromosome 17q21 linked ORMDL3 (orosomucoid 1-like 3) to the risk of developing childhood asthma . This association has since been reproduced in multiple independent studies [7–14]. However, little work has been done to elucidate the biological and functional relevance of this gene in asthma. The disadvantage of these association studies is that they cannot differentiate between true causal SNPs and non-causal variants simply in linkage disequilibrium with disease-causing genes. It is therefore imperative to validate GWAS data through functional studies that confirm the biological relevance of a gene in disease.
SNP variants have also linked ORMDL3 to inflammatory bowel disease (IBD) and Type I diabetes, suggesting that ORMDL3 may be involved in dysregulation of the immune system [15, 16]. Association of ORMDL3 in both asthma and IBD is of interest because the lung and gut are composed of similar mucosal surface cells and these tissues are exposed to many potentially harmful antigens and allergens requiring tight regulation of the mucosal immune system . This unique system is responsible for maintaining a delicate equilibrium between antigen responsiveness and tolerance and is therefore responsible for preventing hyper-reactivity . Inappropriate immune responses to foreign components or commensal bacteria can lead to inflammation characteristic of asthma and IBD. Furthermore, the polymorphisms may be involved in regulation of mRNA expression of 17q21 locus genes, including ORMDL3. The expression of ORMDL3 was recently associated with elevated levels of IL-17 secretion  and ORMDL3 was expressed at higher levels in the peripheral blood of patients with recurrent wheeze compared to controls . This correlation further supports the hypothesis that ORMDL3 is involved in immunity.
The ORMDL3 gene is a member of a family of conserved endoplasmic reticulum (ER)-localized transmembrane proteins . The functions of the ORMDL proteins are currently unknown, but a recent study suggested that ORMDL3 is involved in ER-mediated Ca2+ homeostasis and activation of the unfolded protein response (UPR) – ORMDL3 may inhibit sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) activity [21, 22]. Disruptions to ER Ca2+ concentrations can cause protein misfolding, and accumulation of these unfolded proteins can lead to ER stress [23, 24]. UPR signaling cascades are initiated in response to this stress and have been shown to activate the JNK-AP-1 and NF-κB-IKK pathways [25–27]. The ER stress response and UPR, caused by changes in ORMDL3 expression, can initiate inflammation through induction of cytokine production. This mechanism may explain the role of ORMDL3 in asthma pathogenesis. Indeed, Miller et al. have shown that in mice ORMDL3 is an allergen and cytokine (IL-4 or IL-13) inducible ER gene expressed predominantly in airway epithelial cells, and that it activates the ATF6 pathway of the ER localized UPR regulating expression of metalloprotease, chemokine, and oligoadenylate synthetase genes .
Although the symptoms of asthma are largely driven by dysregulated T helper type 2 (TH2) responses, innate immune responses are also involved in asthma pathogenesis [29, 30]. Airway epithelia are central to host defense and immune regulation. These cells are among the first to encounter environmental insults and play an important role in shaping downstream immune responses. Any dysregulation of the innate immune response can result in hypersensitivity to environmental factors, leading to asthma symptoms.
Given the multiple lines of evidence suggesting that ORMDL3 is involved in immunity, we investigated the role of the gene in innate immune responses of airway cells. We hypothesized that elevated ORMDL3 levels result in heightened inflammatory responses that are associated with the asthmatic phenotype. Increased levels of ORMDL3 protein may in turn disrupt ER homeostasis, leading to ER overload and activation of the UPR, initiating inflammatory responses. Using an in vitro model, we manipulated ORMDL3 expression in airway cells to determine whether a difference in basal ORMDL3 expression affected inflammatory responses or activation of the UPR before and after stimulation.
Materials and methods
1HAEo¯ (1HAE) cells (SV40-transformed normal human airway epithelial cells) were cultured in DMEM-high glucose medium with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 1 mM sodium pyruvate (HyClone). A549 cells (adenocarcinomic human alveolar basal epithelial cells) were cultured in F-12K medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 1 mM sodium pyruvate (HyClone). Cells were incubated in a 37°C, 5% CO2 incubator. All cells were cultured under non-polarizing conditions.
Cloning ORMDL3 cDNA into pEGFP-N1 vector
The ORMDL3 gene was amplified from cDNA using forward primer 5′-CTAAGAATTCATGAATGTGGGCACAGCGCAC-3′ and reverse primer 5′-TACTGGTACCCCGTACTTATTGATTCCAAAAATCCGGACT-3′, introducing Eco RI and Kpn I restriction endonuclease sites, respectively. The ORMDL3 PCR product was then inserted into a pEGFP-N1 eukaryotic expression vector (Clontech). ORMDL3 and eGFP are in frame and produce a fusion protein with eGFP expressed at the C-terminus of ORMDL3. The construct was verified by sequencing and is denoted as pEGFP-ORMDL3. Protein is denoted as ORMDL3-eGFP.
A549 and 1HAE cell lines were transfected with pEGFP-ORMDL3, scramble (non-specific) or ORMDL3-specific siRNA (pre-designed by Qiagen) using Amaxa® Cell Line Nucleofector® Kit T (Lonza). Two ORMDL3-specific siRNAs were used. Concentrations used for transfection represent pooled siRNA concentration. Cells were seeded into a 24-well plate (BD Biosciences) at a density of 2x105 cells/well for A549 cells or 1x105 cells/well for 1HAE cells.
Cell stimulation and immune response quantification
Twenty-four hours post-transfection, cells were stimulated with TNF-α (200 ng/ml) (eBioscience), E. coli K12 LPS (100 μg/ml) (InvivoGen), S. typhimurium flagellin (10-200 ng/ml) (InvivoGen), or IL-1β (200 ng/ml) (eBioscience). Stimulants and their concentrations were chosen based on published literature or past experiments [31–34]. Cells were stimulated for 24 hours. Supernatants were collected and analyzed for cytokine secretion. Pro-inflammatory cytokines, IL-6 and IL-8, were detected and quantified using Human IL-6 and IL-8 Ready-Set-Go!® ELISA kits (eBioscience). Experiments were repeated three times (n = 3).
ER stress induction and UPR activation
Cells were stimulated with tunicamycin (200 μg/mL) (Calbiochem) or thapsigargin (10 μM) (Sigma) for 2 or 4 hours to activate the UPR. For ORMDL3 knockdown cells, stimulation was performed 24 hours post-transfection. RNA was extracted and expression of genes XBP-1u, XBP-1s, and CHOP were then quantified as markers of UPR activation. For measurement of p-eIF2α levels by Western blot, lysates from unstimulated cells with ORMDL3 knockdown were collected 24 hours post-transfection. Experiments were repeated three times (n = 3).
RNA isolation and reverse transcription
RNA was extracted from lysates using E.Z.N.A.® Total RNA Kit (Omega Bio-Tek) according to the manufacturer’s protocol. Extracted RNA was reverse transcribed into cDNA using the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen). Complement DNA was diluted to 200 ng/μl prior to quantification of gene expression by qPCR. This method was followed for all samples, unless otherwise stated (see PCR Array).
Quantification of ORMDL3 mRNA expression
Quantitative PCR primer sequences
Forward (5′ → 3′)
Reverse (5′ → 3′)
Western blot analysis
Cells were lysed in 50 μl RIPA Buffer + 1x HALT™ protease inhibitor (Thermo Scientific). Cell debris were removed by centrifugation: 18,000 x g for 10 min at 4°C. Proteins were analyzed by standard Western blotting protocols where they were transferred onto Immobilon®-FL transfer membrane (Millipore). Antibodies used for Western blot analysis were: monoclonal anti-GFP antibody 1:10,000 (Clontech), anti-ACTB antibody 1:6,000 (Cell Signaling), anti-p-eIF2α 1:500 (Cell Signaling) and IRDye® 680 or 800 secondary antibodies 1:8000 (Li-cor). Western blots were visualized using an Odyssey Infrared Imaging System (Li-cor).
1HAE cells co-transfected with pEGFP-ORMDL3 and ORMDL3 siRNA (low ORMDL3 expression) were compared to cells co-transfected with pEGFP-ORMDL3 and scramble siRNA (high ORMDL3 expression) at two time-points (2 and 24 hours) after TNF-α stimulation. Extracted RNA was reverse transcribed into first strand cDNA using the RT2 First Strand Kit (SABiosciences, Qiagen). Protocol as described by the manufacturer was followed.
Two RT2 Profiler PCR arrays (SABiosciences, Qiagen), profiling expression of 84 genes each, were used: Human Cytokines & Chemokines and Allergy & Asthma (see Additional file 1 for complete list). Complementary DNA template was mixed with RT2 SYBR® Green qPCR Mastermix (SABiosciences, Qiagen) as follows: 1350 μL SYBR Green Master Mix, 1248 μL nuclease-free H2O, and 102 μL cDNA (~200 ng/μL). Note: these volumes were used as recommended by the manufacturer for use with a 7300 Real Time PCR System (Applied Biosystems). Template was then aliquoted into PCR plates containing pre-dispensed primers. Cycler program as provided by the manufacturer was used. Results were analyzed using the PCR Array Data Analysis Web Portal.
Data are shown as mean ± SEM of three separate experiments. Results were analyzed using one-way ANOVA with Bonferroni post-test. Statistical analysis was performed using GraphPad Prism5 (GraphPad Software, Inc.). Differences with p < 0.05 were considered significant.
ORMDL3 modulation in airway cells
In order to determine functional impact of ORMDL3 modulation, knockdown of the gene was performed using siRNAs. A549 and 1HAE cells were transfected with scramble (non-specific) or ORMDL3- specific siRNA. Modeling variation expected to occur in the human population, we achieved 40-70% knockdown of ORMDL3 gene expression using siRNA concentrations of 50 nM-500 nM. We also confirmed that ORMDL3- specific siRNA did not affect expression of genes in the same family, ORMDL1 or ORMDL2 (Additional file 2). Sequences of primers used for qPCR are listed in Table 1.
ORMDL3 has 84% and 80% protein sequence homology to ORMDL1 and ORMDL2, respectively. This presented a challenge for confirming knockdown of ORMDL3 protein because commercially available antibodies detect all three proteins. Therefore, we were unable to show ORMDL3 protein knockdown in cells transfected with siRNA alone. To overcome this limitation, we constructed a fusion protein, where ORMDL3 is tagged with an eGFP protein. Co-transfection of this overexpression plasmid with ORMDL3-specific siRNA enabled us to knockdown ORMDL3 and detect changes at the protein level using an anti-GFP antibody.
ORMDL3 knockdown does not affect IL-6 or IL-8 production following innate immune activation
ORMDL3 knockdown does not enhance UPR activation upon stimulation
We next explored the effects of ORMDL3 expression on activation of the UPR. Initiation of the UPR is mediated by one or more of the ER-membrane protein sensors: PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol requiring enzyme 1 (IRE1), and activating transcription factor-6 (ATF6) . Activation of any of the three pathways initiates signaling cascades that mediate changes to relieve ER stress. The gene XBP-1 is a substrate for IRE1 ribonuclease . Upon activation of the IRE1 pathway, the IRE1 ribonuclease removes a 26-bp intron from the unspliced variant, XBP-1u, which results in the spliced variant, XBP-1s. This spliced variant is the active form of the gene that contributes to ER stress responses. CHOP transcription, in contrast, can be induced by the PERK and ATF6 pathways . Phosphorylated eIF2α (p-eIF2α) is an early marker of PERK pathway activation and is upstream of CHOP induction . Expression changes in these three genes that signify UPR activation, XBP-1u, XBP-1s, and CHOP, were determined by qPCR. We also evaluated phosphorylation of eukaryotic initiation factor 2α (eIF2α) by Western blot, as modulation of ORMDL3 expression has been reported to influence eIF2α phosphorylation .
At baseline (unstimulated cells), variation in ORMDL3 expression did not induce UPR activation in A549 or 1HAE cells (Additional file 2). 1HAE cells with ORMDL3 knockdown were also stimulated with tunicamycin or thapsigargin (Figure 3C-D). In both conditions, ORMDL3 knockdown did not show increased UPR activation compared to the negative control. Furthermore, levels of phosphorylated-eIF2α were indistinguishable between ORMDL3 knockdown cells and controls (Figure 3E).
Impact of ORMDL3 knockdown on the expression of multiple genes involved in inflammation, asthma & allergy
To expand our search for immune functions potentially altered by ORMDL3, the expression of 168 genes was determined at two time points (2 and 24 hours) following stimulation with TNF-α. We performed PCR arrays to profile expression of cytokines, chemokines, and key genes involved in asthma and allergy (a complete list of genes that were studied can be found in Additional file 1).
The same arrays were performed on cells stimulated for 2 hours with TNF-α. The same conditions for “high” and “low” ORMDL3 expression were used. From our results, we identified only one gene, IL23A, that was differentially regulated by more than 1.5 fold (fold regulation −2.37) and amplified at cycle <30. Replication and comparison of IL23A expression between knockdown conditions yielded no significant difference. No other genes, as identified in the previous arrays, were found to be differentially regulated at this time point. These results suggest that ORMDL3 variation does not have a meaningful impact on expression of a large panel of immune-related genes in airway epithelial cells.
Asthma is a complex disease affecting many individuals in the developed world. Genome-wide association studies have recently been used to identify genetic causes for such complex diseases. One particular gene, ORMDL3, is of interest because of its association with asthma, IBD, and Type I diabetes – all of which are caused by immune-mediated pathology [6, 10, 22, 38, 39]. The gene ORMDL3 is an ER-membrane protein and is potentially involved in Ca2+-signaling in the ER and sphingolipid synthesis [20, 21, 40]. It has also been correlated to activation of the UPR, though the mechanisms remain unclear . Activation of the UPR may be biologically relevant, as ER stress, the UPR, and inflammation have all been linked . However, the functional role ORMDL3 in the pathogenesis of asthma has yet to be elucidated.
Airway epithelial cells play an important role in innate immunity and in the development of asthma. Current findings in literature indicate that ORMDL3 is involved in immunity and that asthmatics have higher expression of the gene than non-asthmatics [18, 21, 22]. A recent study by Miller et al. also investigated the role of ORMDL3 in airway epithelial cells. They reported that in vitro overexpression of ORMDL3 activated the ATF6 pathway of the UPR and induced expression of several genes with potential importance in the pathogenesis of asthma . Our investigation, in contrast, focuses on the effect of variation of ORMDL3 expression levels, at baseline, on the innate immune responsiveness of airway epithelial cells. By manipulating ORMDL3 expression in vitro to mimic differences in gene expression established between asthmatics and healthy individuals, we aimed to understand the role of ORMDL3 on the innate immune response and UPR activation status in airway epithelial cells. This method ensured control and the confidence that any effect on the innate immune response was in fact correlated with a change in ORMDL3 expression levels. If the same experiments were performed on ex vivo airway cells of patients, genetic and other differences between individuals could have affected the results.
After knockdown of ORMDL3 in vitro, cells were stimulated with cytokines (TNF-α, IL-1β) or common microbial components (LPS, flagellin). We monitored production of interleukin-6 (IL-6) and interleukin-8 (IL-8) (alias CXCL8), two pro-inflammatory cytokines produced by airway cells that are relevant in asthma pathogenesis. Specifically, IL-6 is elevated in individuals with asthma  and is also regulated by ATF6 during activation of the UPR . Similarly, transfection of ORMDL3 into human airway epithelial cells triggers ATF6 activation and IL-8 secretion . However, in our experimental system, variation in ORMDL3 expression levels did not affect NF-κB-induced innate immune production of IL-6 and IL-8 in airway epithelial cells.
We next explored the effects of ORMDL3 expression on activation of the UPR. UPR signaling cascades are initiated in response to ER stress, and restoration of homeostasis is achieved by attenuating translation, restoring protein folding, or degrading misfolded proteins . Although often associated with abnormal physiological conditions, the UPR plays a central beneficial role in normal physiology; as illustrated by the role of the UPR in terminal B cell differentiation which requires a massive increase in the biosynthetic capacity to synthesize antibodies in response to infection . However, the ER stress response and UPR can also initiate inflammation through induction of cytokine production or activation of transcriptional regulators of inflammatory genes. Cytokines IL-6 and IL-8 are examples of genes that may be induced by UPR activation . ER stress and the UPR have been implicated in many immune-related diseases including IBD, diabetes, chronic obstructive pulmonary disease (COPD), arthritis, and neurodegenerative inflammatory diseases . It is poorly understood whether ER stress is an underlying cause of disease or if its induction is a result of chronic inflammation. Indeed, it is possible that environment factors such as infection or inhalation of smoke particles can activate the UPR, triggering the onset of lung disease in genetically predisposed individuals . However, it is also possible that ER stress is exacerbated by inflammation and contributes to the perpetuation of the disease.
Cantero-Recasens et al. previously reported that ORMDL3 overexpression activated the PERK pathway, but did not affect the IRE1 pathway of the UPR . In contrast, Miller et al. reported that ORMDL3 overexpression activated the ATF6 pathway, but not the PERK or IRE1 pathways . In our study, we chose four markers of UPR activation: XBP-1u, XBP-1s, CHOP, and p-eIF2α. With activation of the UPR, we expect downregulation of XBP-1u and upregulation of XBP-1s and CHOP. However, our results demonstrate that knockdown of ORMDL3 does not activate the UPR, in either unstimulated or stimulated cells. Immunoblot analysis also showed no change in p-eIF2α levels with ORMDL3 knockdown. Furthermore, downstream markers of UPR activation, IL-6 and IL-8 cytokines, were produced at similar levels in unstimulated cells with varying ORMDL3 levels. This further supports our results that ORMDL3 does not activate the UPR. Differences in our results compared to previous work might be due to the different types of cells, conditions, or markers used. It is possible that the effects of variation in ORMDL3 expression are a cell type-dependent phenomenon. While no effect on the inflammatory response was detected in airway cells, other cells types such as dendritic cells or T cells may be affected by altered ORMDL3 expression. Observations made by Lluis et al. suggest that the 17q21 locus may potentially play a role in T-cell development .
Taking a broader approach, PCR arrays looking at expression of 168 common immunity genes were performed. We reasoned that although ORMDL3 levels may not affect the production of IL-6 or IL-8 cytokines, perhaps they were impacting gene expression of other important immune genes, such as IL-33, IL-25 and TSLP, which have all been implicated in asthma pathogenesis . Verification of differential expression of these genes at a transcript level, however, did not show any significant changes between the ORMDL3 knockdown conditions. This suggests that altering ORMDL3 expression does not have a profound effect on the expression of innate immune genes upon stimulation in the airway epithelia. However, there may be other genes that are affected that were not investigated in this study. Pfeifer et al. recently showed that IL-17C cytokine is expressed by human bronchial epithelial cells and is induced by bacterial infection . It may be worthwhile in future experiments to investigate a broader range of immune-related genes. Interestingly, we did not observe changes to expression of the genes reported by Miller et al., MMP-9, CCL-20, CXCL-10, CXCL-11, or IL-8. This variance may be explained by differences in experimental conditions. Our study examined outcomes in gene expression after stimulation of cells co-transfected with ORMDL3 and ORMDL3- specific siRNA, while the other study used a different experimental approach.
Although this study focused exclusively on the potential role of ORMDL3 in asthma pathogenesis, it is possible that neighboring genes such as GSDML contribute to disease susceptibility at this locus. Many groups consider ORMDL3 as an ‘asthma gene’; however, it should be acknowledged that the identified SNPs associating this gene to asthma susceptibility are not located in the gene itself. Even so, these polymorphisms have been consistently correlated with increased odds of asthma risk, highlighting the importance of this locus in disease susceptibility [6–11, 13, 14].
Our data show that variation in ORMDL3 expression is not correlated with differential innate immune responses to stimuli or activation of the UPR in vitro in airway epithelial cells. Taken together, our results are biologically relevant because they suggest that normal human variation of ORMDL3 expression is not likely an important factor in increasing the innate immune response of airway cells we observe in asthmatics. Despite these results, this gene remains an important candidate for asthma susceptibility. More research is required to elucidate its role in asthma pathogenesis and its potential role as an initial trigger of inflammation. By increasing our understanding of the mechanisms responsible for allergic and atopic disease development, new treatments can then be developed. Thus, we can reduce inflammatory responses by targeting the potential triggers, rather than the symptoms, of the disease. In doing so, we will ultimately reduce the morbidity, mortality, and socio-economic burden of asthma and related allergic diseases.
KJH was funded by the Child & Family Research Institute and AllerGen Networks of Centers of Excellence. SET holds the Aubrey J Tingle Professorship in Pediatric Immunology and is a clinical scholar of the Michael Smith Foundation for Health Research. This work was supported by funding from the AllerGen Networks of Centers of Excellence.
- Cho SH: Pharmacogenomic approaches to asthma treatment. Allergy Asthma Immunol Res. 2010, 2 (3): 177-182. 10.4168/aair.2010.2.3.177.PubMed CentralView ArticlePubMed
- Davies DE, Djukanovic R, Holgate ST: Application of functional genomics to study of inflammatory airways disease. Thorax. 1999, 54 (1): 79-81. 10.1136/thx.54.1.79.PubMed CentralView ArticlePubMed
- Gu ML, Dong XQ, Zhao J: New insight into the genes susceptible to asthma. J Asthma. 2010, 47 (2): 113-116. 10.3109/02770900903498442.View ArticlePubMed
- Ober C, Hoffjan S: Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun. 2006, 7 (2): p. 95-p. 100.View Article
- Vercelli D: Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008, 8 (3): 169-182. 10.1038/nri2257.View ArticlePubMed
- Moffatt MF: Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007, 448 (7152): 470-473. 10.1038/nature06014.View ArticlePubMed
- Galanter J: ORMDL3 gene is associated with asthma in three ethnically diverse populations. Am J Respir Crit Care Med. 2008, 177 (11): 1194-1200. 10.1164/rccm.200711-1644OC.PubMed CentralView ArticlePubMed
- Halapi E: A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet. 2010, 18 (8): 902-908. 10.1038/ejhg.2010.38.PubMed CentralView ArticlePubMed
- Hirota T: Genetic polymorphism regulating ORM1-like 3 (Saccharomyces cerevisiae) expression is associated with childhood atopic asthma in a Japanese population. J Allergy Clin Immunol. 2008, 121 (3): 769-770. 10.1016/j.jaci.2007.09.038.View ArticlePubMed
- Moffatt MF: A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010, 363 (13): 1211-1221. 10.1056/NEJMoa0906312.PubMed CentralView ArticlePubMed
- Ferreira MA: Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia. Eur J Hum Genet. 2011, 19 (4): 458-464. 10.1038/ejhg.2010.191.PubMed CentralView ArticlePubMed
- Sleiman PM: ORMDL3 variants associated with asthma susceptibility in North Americans of European ancestry. J Allergy Clin Immunol. 2008, 122 (6): 1225-1227. 10.1016/j.jaci.2008.06.041.View ArticlePubMed
- Tavendale R: A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol. 2008, 121 (4): 860-863. 10.1016/j.jaci.2008.01.015.View ArticlePubMed
- Wu H: Genetic variation in ORM1-like 3 (ORMDL3) and gasdermin-like (GSDML) and childhood asthma. Allergy. 2009, 64 (4): 629-635. 10.1111/j.1398-9995.2008.01912.x.PubMed CentralView ArticlePubMed
- Barrett JC: Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009, 41 (6): 703-707. 10.1038/ng.381.PubMed CentralView ArticlePubMed
- Barrett JC: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008, 40 (8): 955-962. 10.1038/ng.175.PubMed CentralView ArticlePubMed
- Neurath MF, Finotto S, Glimcher LH: The role of Th1/Th2 polarization in mucosal immunity. Nat Med. 2002, 8 (6): 567-573. 10.1038/nm0602-567.View ArticlePubMed
- Lluis A: Asthma-associated polymorphisms in 17q21 influence cord blood ORMDL3 and GSDMA gene expression and IL-17 secretion. J Allergy Clin Immunol. 2011, 127 (6): p. 1587-p. 1594. e6View ArticlePubMed
- Jin R: Mechanisms elevating ORMDL3 expression in recurrent wheeze patients: role of Ets-1, p300 and CREB. Int J Biochem Cell Biol. 2012, 44 (7): 1174-1183. 10.1016/j.biocel.2012.04.007.View ArticlePubMed
- Hjelmqvist L: ORMDL proteins are a conserved new family of endoplasmic reticulum membrane proteins. Genome Biol. 2002, 3 (6): p. RESEARCH0027-View Article
- Cantero-Recasens G: The asthma-associated ORMDL3 gene product regulates endoplasmic reticulum-mediated calcium signaling and cellular stress. Hum Mol Genet. 2009, 19 (1): 111-121.View Article
- McGovern DP: Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010, 42 (4): 332-337. 10.1038/ng.549.PubMed CentralView ArticlePubMed
- Hotamisligil GS: Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010, 140 (6): 900-917. 10.1016/j.cell.2010.02.034.PubMed CentralView ArticlePubMed
- McGuckin MA: ER stress and the unfolded protein response in intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2010, 298 (6): G820-G832. 10.1152/ajpgi.00063.2010.View ArticlePubMed
- Cullinan SB, Diehl JA: Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol. 2006, 38 (3): 317-332. 10.1016/j.biocel.2005.09.018.View ArticlePubMed
- Deng J: Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol. 2004, 24 (23): 10161-10168. 10.1128/MCB.24.23.10161-10168.2004.PubMed CentralView ArticlePubMed
- Hu P: Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol. 2006, 26 (8): 3071-3084. 10.1128/MCB.26.8.3071-3084.2006.PubMed CentralView ArticlePubMed
- Miller M: ORMDL3 is an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6. Proc Natl Acad Sci USA. 2012, 109 (41): 16648-16653. 10.1073/pnas.1204151109.PubMed CentralView ArticlePubMed
- Kim HY, DeKruyff RH, Umetsu DT: The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010, 11 (7): 577-584. 10.1038/ni.1892.PubMed CentralView ArticlePubMed
- Umetsu DT: Asthma: an epidemic of dysregulated immunity. Nat Immunol. 2002, 3 (8): 715-720. 10.1038/ni0802-715.View ArticlePubMed
- Palmberg L: Induction of IL-8 production in human alveolar macrophages and human bronchial epithelial cells in vitro by swine dust. Thorax. 1998, 53 (4): 260-264. 10.1136/thx.53.4.260.PubMed CentralView ArticlePubMed
- Shanks KK: Interleukin-8 production by human airway epithelial cells in response to Pseudomonas aeruginosa clinical isolates expressing type a or type b flagellins. Clin Vaccine Immunol. 2010, 17 (8): 1196-1202. 10.1128/CVI.00167-10.PubMed CentralView ArticlePubMed
- Yang Y: Regulation of interleukin-1beta and interleukin-1beta inhibitor release by human airway epithelial cells. Eur Respir J. 2004, 24 (3): 360-366. 10.1183/09031936.04.00089703.View ArticlePubMed
- Nagaraju K: A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol. 1998, 113 (3): 407-414. 10.1046/j.1365-2249.1998.00664.x.PubMed CentralView ArticlePubMed
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29 (9): e45-10.1093/nar/29.9.e45.PubMed CentralView ArticlePubMed
- Isler JA, Skalet AH, Alwine JC: Human cytomegalovirus infection activates and regulates the unfolded protein response. J Virol. 2005, 79 (11): 6890-6899. 10.1128/JVI.79.11.6890-6899.2005.PubMed CentralView ArticlePubMed
- Samali A: Methods for monitoring endoplasmic reticulum stress and the unfolded protein response. Int J Cell Biol. 2010, 2010: 830307-PubMed CentralPubMed
- Lees CW: New IBD genetics: common pathways with other diseases. Gut. 2011, 60 (12): 1739-1753. 10.1136/gut.2009.199679.View ArticlePubMed
- Saleh NM: Genetic association analyses of atopic illness and proinflammatory cytokine genes with type 1 diabetes. Diabetes Metab Res Rev. 2011, 27 (8): 838-843. 10.1002/dmrr.1259.PubMed CentralView ArticlePubMed
- Han S: Orm1 and Orm2 are conserved endoplasmic reticulum membrane proteins regulating lipid homeostasis and protein quality control. Proc Natl Acad Sci USA. 2010, 107 (13): 5851-5856. 10.1073/pnas.0911617107.PubMed CentralView ArticlePubMed
- Broide DH: Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992, 89 (5): 958-967. 10.1016/0091-6749(92)90218-Q.View ArticlePubMed
- Shi Y: Role of GRP78/BiP degradation and ER stress in deoxynivalenol-induced interleukin-6 upregulation in the macrophage. Toxicol Sci. 2009, 109 (2): 247-255. 10.1093/toxsci/kfp060.PubMed CentralView ArticlePubMed
- Ma Y, Hendershot LM: The stressful road to antibody secretion. Nat Immunol. 2003, 4 (4): 310-311. 10.1038/ni0403-310.View ArticlePubMed
- Hasnain SZ: The interplay between endoplasmic reticulum stress and inflammation. Immunol Cell Biol. 2012, 90 (3): 260-270. 10.1038/icb.2011.112.View ArticlePubMed
- Adair-Kirk TL, Atkinson JJ, Senior RM: Smoke particulates stress lung cells. Nat Med. 2008, 14 (10): 1024-1025. 10.1038/nm1008-1024.View ArticlePubMed
- Paul WE, Zhu J: How are T(H)2-type immune responses initiated and amplified?. Nat Rev Immunol. 2010, 10 (4): 225-235. 10.1038/nri2735.PubMed CentralView ArticlePubMed
- Pfeifer P: IL-17C is a Mediator of Respiratory Epithelial Innate Immune Response. Am J Respir Cell Mol Biol. 2012, [Epub ahead of print]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.